Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 1/2000

01-07-2000 | Review Article

Humoral Immune Response to Influenza Vaccination in Patients from High Risk Groups

Authors: Professor Lidia B. Brydak, Magdalena Machala

Published in: Drugs | Issue 1/2000

Login to get access

Abstract

Influenza is one of the most common respiratory diseases. Infections caused by this virus may be very serious and can lead to severe complications. So far, the most effective method of protection against influenza is annual vaccination. The Advisory Committee on Immunisation Practices recommends vaccination against influenza for some groups of people. Unfortunately, in spite of these clear indications, a large number of patients are not vaccinated.
This article reviews the current scientific literature on immunological response to influenza vaccination in patients who are at especially high risk for serious post-influenza complications and for whom immunisation against this virus is strongly recommended. Results of studies carried out in Poland and other countries in elderly people, in patients with pulmonary diseases, renal diseases, diabetes mellitus, cancer and haemophilia, and in those with HIV infection are presented. In this review, we focus on the immune response to haemagglutinin. There are some discrepancies between the results of studies carried out by different authors in high risk groups of patients. Some investigations indicated poorer humoral response to influenza vaccine in these groups, while others showed responses comparable to those in healthy individuals. These differences may be explained by differences in types and stages of the chronic diseases, in the treat-ment and composition of influenza vaccines, and also patients’ ages, vaccination history and prevaccination antibody titres. Influenza vaccines are well tolerated in high risk patients, and all adverse reactions are generally mild and similar to those observed in healthy people. Although, in some cases, immunological responses to influenza vaccination measured in the whole study group were poor, there were some individual patients who, after vaccination, developed antihaema-glutinin antibody titres which are considered to give protection against the infection or contribute to a milder course of the disease.
Literature
1.
Brydak LB. Influenza and its prophylaxis. Springer PWN: Warsaw, 1998
2.
Van Hoecke Ch, Prikazsky V, Ütö I. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 1996; 42: 190–8PubMedCrossRef
3.
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889–93PubMedCrossRef
4.
Brydak LB, Bialek J, Rudnicka H, et al. Seroconversion assessment in a billeted military medical university student group after antiinfluenza vaccinations in 1993/1994 in Poland. Anti-infect Drugs Chemother 1997; 15(1): 13–6
5.
Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics 1996; 9(3): 75–8PubMedCrossRef
6.
Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48: RR–4
7.
8.
Groothius JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 1991; 87(6): 823–8
9.
Serwint J. Pediatrician-dependent barriers in influenza vaccine administration. Pediatric Infect Dis J 1993; 12(11): 956–8CrossRef
10.
Committee on Infectious Diseases, American Academy of Pediatrics. Immunization in special clinical circumstances. In: Report of the Committee on Infectious Diseases. Elk Grove Village (IL): American Academy of Pediatrics, 1991; 22: 46–66
11.
Glathe H, Bigl S, Grosche A. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people. Vaccine 1993; 11(7): 702–5PubMedCrossRef
12.
Ghendon Y. The immune response to influenza vaccines. Acta Virol 1990, 34: 295–304PubMed
13.
Center for Disease Control. Concepts and procedures for laboratory-based influenza surveillance. Atlanta (GA): Center for Disease Control, 1982
14.
Manuguerra JC, Hannoun C. Influenza and other viral respiratory diseases. Surveillance and laboratory diagnosis. Paris: Institute Pasteur, 1999: 188–90
15.
Ada GL, Jones PD. The immune response to influenza infection. Curr Topics Microbiol Immunol 1986; 128: 1–54CrossRef
16.
Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (revision). 1997 Mar 12: CPMP/BWP/214/96
17.
Commission of the European Communities. The rules governing medicinal products in the european community. Brussels: Commission of the European Communities, 1992; 3, 2: 93–8
18.
Nichol KL, Margolis KL, Wouremna J, et al. Effectiveness of influenza vaccine in the elderly. Gerontology 1996; 42: 274–9PubMedCrossRef
19.
Influenza vaccination coverage levels in selected sites: United States, 1989. MMWRMorb Mortal Wkly Rep 1990; 39: 159–67
20.
Lennox IM, Macphee GJ, McAlpine CH, et al. Use of influenza vaccine in long-stay geriatric units. Age Ageing 1990; 19: 169–72PubMedCrossRef
21.
Morgan R, King D, Turnbull CJ. Influenza vaccination: do the aged reap the benefit? Postgrad Med J 1995; 71: 22–3PubMedCrossRef
22.
Ikematsu H, Kashiwagi S. Efficacy and adverse reactions of influenza vaccine in the elderly. Nippon Rinsho 1997 Oct; 55(10): 2751–7PubMed
23.
Zei T, Neri M, Iorio AM. Immunogenicity of trivalent subunit and split influenza vaccines (1989–90 winter season) in volunteers of different groups of age. Vaccine 1991 Sep; 9: 613–7PubMedCrossRef
24.
Gross PA, Russo C, Teplitzky M, et al. Time to peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1996 May; 3(3): 361–2PubMed
25.
Govaert ThME, Sprenger MJW, Dinant GJ, et al. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994; 12(13): 1185–9
26.
Brydak LB, Ordyñska E, Wasilewski B, et al. Immunogenicity of trivalent subunit influenza vaccine in elderly people with chronic medical conditions vaccinated in 1993 in Poland. Antiinfect Drugs Chemother 1997; 15(1): 9–12
27.
Govaert ThME, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993; 307: 988–90PubMedCrossRef
28.
McElhaney JE, Meneilly GS, Beattie BL, et al. The effect of influenza vaccination on 112 production in healthy elderly: implications for current vaccination practices. J Gerontol 1992; 47: M3–M8PubMedCrossRef
29.
McElhaney JE, Meneilly GS, Lechelt KE, et al. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 1993; 11(10): 1055–60PubMedCrossRef
30.
Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks gestation. Pediatrics 1991; 88: 527–32PubMed
31.
Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatric Clin North Am 1994; 41(2): 277–310
32.
Daubeney P, Taylor CJ, McGaw J, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk children aged 6 months to 4 years. BJCP 1997; 51(2): 87–90
33.
Li M, Groothuis JR, Lehr MV, et al. Maturation of antibody response to influenza vaccine in premature infants. Immunol Infect Dis 1995; 5: 211–7
34.
Levandovski RA, Regnery HL, Staton E, et al. Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics 1991; 88; 5: 1031–6
35.
Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children. Vaccine 1994; 12(2): 139–41PubMedCrossRef
36.
Künzel W, Glathe H, Engelmann H, et al. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14, 12: 1108–10CrossRef
37.
Pyhälä R, Kumpulainen V, Alanko S, et al. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990–1992. Vaccine 1994; 12(10): 947–52PubMedCrossRef
38.
Beyer WEP, Palache AM, Sprenger MJW, et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996; 14(14): 1331–9PubMedCrossRef
39.
Groothius JR, Levin MJ, Lehr MV, et al. Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine 1992; 10(4): 221–5CrossRef
40.
Englund JA, Mbawuike I, Hammill H, et al. Maternal immunization with influenza or tetanus toxoid vaccine for passive protection in young infants. J Infect Dis 1993; 168: 647–56PubMedCrossRef
41.
Little JW, Hall WJ, Douglas RG, et al. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. A Rev Respir Dis 1978; 118: 295–303
42.
Quarles van Ufford WJ, Savelberg PJ. Asiatic influenza in allergic patients with bronchial asthma. Int Arch Allergy Appl Immunol 1959; 15: 189–92CrossRef
43.
44.
Committee of Infectious Diseases. Influenza. In: 1994 Red Book. Elk Grove Village (IL): American Academy of Pediatrics, 1994: 275–83
45.
Banks J, Bevan C, Fennerty A, et al. Association between rise in antibodies and increase in airway sensitivity after intramuscular injection of killed influenza virus in asthmatic patients. Eur J Respir Dis 1985; 66: 268–72PubMed
46.
Oullette JJ, Reed CE. Increased response of asthmatic subjects to methacholine after influenza vaccine. J Allergy 1965; 36: 558–63CrossRef
47.
Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 1998 Jan 31; 351: 326–31PubMedCrossRef
48.
Reid DW, Bromly CL, Stenton SC, et al. A double-blind placebo-controlled study of the effect of influenza vaccination on airway responsiveness in asthma. Respir Med 1998; 92: 1010–1PubMedCrossRef
49.
Ghirga G, Ghirga P, Rodino P, et al. Safety of the subunit influenza vaccine in asthmatic children. Vaccine 1991; 9(12): 913–4PubMedCrossRef
50.
Bell TD, Chai H, Berlow B, et al. Immunization with killed influenza virus in children with chronic asthma. Chest 1978; 73(2): 140–5PubMedCrossRef
51.
Park CL, Frank AL, Sullivan M, et al. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone therapy. Pediatrics 1996; 98(2): 196–200PubMed
52.
Mclntosh K, Foy HM, Modlin JF, et al. Multicenter two-dose trials of bivalent influenza a vaccines in asthmatic children aged six to 18 years. J Infect Dis 1977; 136 Suppl.: S645–S7CrossRef
53.
El-Madhun AS, Cox RJ, Scime A, et al. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 1998; 16(2/3): 156–60PubMedCrossRef
54.
Eickhoff TC, Sherman JL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961; 176: 776–82PubMedCrossRef
55.
Erkelens DW. Vaccinate against flu. Diabetes Rev Int 1994; 3(4): 1
56.
Haaheim LR. Diabetics and influenza immunization: missed opportunities. ESWI Influenza Bull 1995; 2: 5
57.
Diepersloot RJA, Bouter KP, Beyer WEP, et al. Humoral immune resopnse and delayed hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 1987; 30: 397–401PubMedCrossRef
58.
Steele RW. Current status of vaccines and immune globulins for children with renal disease. Pediatr Nephrol 1994; 8: 7–10PubMedCrossRef
59.
Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996; 16: 183–91PubMed
60.
Köhler H, Girndt M, Dumann H, et al. Immunodefekt bei Niereninsuffizienz. Teil II. Mechanismen des uremischen Immunodefekts. Dtsch Med Wochenschr 1993b; 118: 790–5
61.
Grzesiowski P. Vaccinations in children with renal diseases [in Polish]. Terapia i Leki 1996; XXIV, XLVI, 7-8: 241–7
62.
Brydak LB, Rajkowski T, Machala M, et al. Humoral antibody response following influenza vaccination in patients with nephrotic syndrome. Antiinfect Drugs Chemother 1998; 16(2): 151–5
63.
Suga T, Niki H, Niikura M, et al. Influenza antibody titers after vaccination of chronic renal failure patients, before and during hemodialysis, or on chronic ambulatory peritoneal dialysis. Tokai I Exp Clin Med 1990; 15: 245–51
64.
Versluis DJ, Beyer WEP, Masurel N, et al. Intact humoral immune response in patients on continuous ambulatory peritoneal dialysis. Nephron 1988; 49: 16–9PubMedCrossRef
65.
Cappel R, Van Beers D, Liensnard C. Impaired humoral and cell-mediated immune response in dialysed patients after influenza vaccination. Nephron 1983; 33: 21–5PubMedCrossRef
66.
Versluis DJ, Beyer WEP, Masurel N. Value of booster immunization with influenza vaccine in patients undergoing haemodialysis. BMJ 1987; 294: 348–50PubMedCrossRef
67.
Grekas D, Alivanis P, Kotzadamis N, et al. Influenza vaccination in chronic hemodialysis patients. The effect of zinc supplementation. Ren Fail 1992; 14(4): 575–8
68.
Nikoskelainen J, Vaananen P, Forsstrom J, et al. Influenza vaccination in patients with chronic renal failure. Scand J Infect Dis 1982; 14(4): 245–51PubMed
69.
Furth SL, Neu AM, McColley SA, et al. Immune response to influenza vaccination in children with renal disease. Pediatr Nephrol 1995; 9: 566–8PubMedCrossRef
70.
Grekas D, Alivanis P, Kiriazopoulou V, et al. Influenza vaccination on renal transplant patients is safe and seerologically effective. Int J Clin Pharmacol Ther Toxicol 1993; 31(11): 553–6PubMed
71.
Brydak LB, Roszkowska-Blaim M, Leszczyñska B, et al. HI antibody kinetics in children with renal failure immunized with inactivated trivalent influenza vaccine. Central European Conference on Modern Vaccinology ‘Vaccines and Immunization’. Poland: Pulawy 1997 May 6–9
72.
Schnaper HW. The immune system in minimal change nephrotic syndrome. Pediatr Nephrol 1989; 3: 101–10PubMedCrossRef
73.
Giacchino F, Quarello F, Pellerey M, et al. Continuous ambulatory peritoneal dialysis improves immunodeficiency in uremic patients. Nephron 1983; 35: 209–10PubMedCrossRef
74.
Koziol-Montewka M, Ksiazek A, Majdan M, et al. Influence of some immune factors on the IL-6 and soluble IL-2 receptor in haemodialized patients. Int Urol Nephrol 1997; 29,3: 369–75CrossRef
75.
Ridgway D, Wolff LJ. Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 1993; 9: 177–92PubMedCrossRef
76.
Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. J Pediatr 1989; 115(1): 33–9PubMedCrossRef
77.
Steinhertz PG, Brown AE, Gross PA, et al. Influenza immunization of children with neoplastic diseases. Cancer 1980; 45: 750–6CrossRef
78.
Brown AE, Steinhertz PG, Miller DR, et al. Immunization against influenza in children with cancer: results of a three-dose trial. J Infect Dis 1982; 145(1): 126PubMedCrossRef
79.
Brydak LB, Rokicka-Milewska R, Jackowska T, et al. Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in Poland. Leuk Lymphoma 1997; 26: 163–9PubMed
80.
Brydak LB, Rokicka-Milewska R, Machala M, et al. Immunogenicity of subunit trivalent influenza vaccine in children with acute lymphoblastic leukemia. Pediatr Infect Dis J 1998; 17: 125–9PubMedCrossRef
81.
Brydak LB, Rokicka-Milewska R, Machala M, et al. Studies on the humoral immune response to hemagglutinin of influenza vaccine in children with acute lymphoblastic leukemia after chemotherapy treatment. Int J Pediatr Hematol Oncol. In press
82.
Bucalossi A, Marotta G, Galieni P, et al. Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1995; 93: 56PubMedCrossRef
83.
Kilbourne ED, Chanock RM, Choppin PW, et al. Influenza vaccines: summary of influenza workshop. V J Infect Dis 1974; 129: 750CrossRef
84.
Schafer AI, Chirchill WH, Ames P, et al. The influence of chemotherapy on response of patients with haematologic malignancies to influenza vaccine. Cancer 1979; 43: 25–30PubMedCrossRef
85.
Smithson WA, Siem RA, Ritts RA, et al. Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr 1978: 632–3
86.
Borella L, Webster RG. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer Res 1971; 31: 420–6PubMed
87.
Sumaya CV, Williams TE. Persistance of antibody after the administration of influenza vaccine to children with cancer. Pediatrics 1982; 69(2): 226–9PubMed
88.
Sumaya CV, Williams TE, Brunell PA. Bivalent influenza vaccine in children with cancer. J Infect Dis 1977; 136: S656–60PubMedCrossRef
89.
Lange B, Shapiro SA, Waldman MTG, et al. Antibody response to influenza immunization of children with acute lymphoblastic leukemia. J Infect Dis 1979; 140(3): 402–6PubMedCrossRef
90.
Brydak LB, Calbecka M. Immunogenicity against influenza in patients with blood cancer disease. Leuk Lymphoma 1999; 32(3-4): 369–74PubMed
91.
Brunell PA. Immunologic response of immunosuppressed children to influenza vaccine. MMWR 1977 Feb 18: 54
92.
Hirota Y, Kaji M, Ide S, et al. The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Vaccine 1996; 14(17/18): 1597–602PubMedCrossRef
93.
94.
Cohn D. Bacterial pneumonia in the HIV-infected patients. Infect Dis Clin North Am 1991; 5: 485–507PubMed
95.
Thurn JR, Henry K. Influenza A pneumonitis in a patient infected with the human immunodeficiency virus (HIV). Chest 1989; 95: 807–10PubMedCrossRef
96.
Nelson KE, Clements ML, Miotti P, et al. The influence human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109: 383–8PubMed
97.
Kroon FP, Van Dissel JT, De Jong JC, et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD+ lymphocytes. AIDS 1994; 8: 469–76PubMedCrossRef
98.
Tasker SA, O’Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998; 16(9/10): 1039–42PubMedCrossRef
99.
Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination on human immunofdeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 1332–6PubMedCrossRef
100.
Schneider MME, Sprenger MJW, Hoepelman IM, et al. Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1. Int J Antimicrob Agents 1996; 6(4): 195–200PubMedCrossRef
101.
Brydak LB, Hryniewicz HJ, Machala M, et al. Humoral response to influenza vaccination in HIV-infected patients. Clin Drug Invest 1999; 17(6): 435–43CrossRef
102.
Huengsberg M, Chakraverty MP, Cooper G, et al. Response to influenza immunization in asymptomatic HIV infected men. Genitourin Med 1995; 71: 355–7PubMed
103.
Boguslawska-Jaworska J, Dobaczewski G. Immunological disorders in children with hemophilia. In: Rokicka-Milewska R. Pediatria [in Polish]. Warszawa: PWN, 1992
104.
Gazengel C, Rothschild C. Immunologic abnormalities in French non-HIV infected hemophiliac children [abstract book no. 430]. International Congress of the WFH: Oct 12–17; Athens, 1992
105.
Madhok R, Gracie A, Lowe GDO, et al. Impaired cell mediated immunity in hemophilia in the absence of infection with human immunodeficiency virus. BMJ 1986; 293: 978–81PubMedCrossRef
106.
Cuthbert RJG, Ludlam CA, Steel CM, et al. Immunologic studies in HIV seronegative haemophiliacs: relationship to blood product therapy. Br J Haematol 1992; 80: 364–9PubMedCrossRef
107.
Brydak LB, Rokicka-Milewska R, Klukowska A, et al. Antibody kinetics in children with hemophilia immunized with influenza vaccine in 1993 in Poland. Int J Pediatrie Hematol Oncol 1998; 5(1): 13–9
108.
Klukowska A, Brydak L, Rokicka-Milewska R, et al. Influenza vaccinations of haemophilic children [in Polish]. Acta Haematol Polonica 1995; 26(3): 305–10
109.
Brydak LB, Rokicka-Milewska R, Machala M, et al. Efficacy of subunit influenza vaccine in previously vaccinated children suffering from hemophilia. Clin Microbiol Infect 1998; 4(10): 589–93PubMedCrossRef
110.
Rokicka-Milewska R, Brydak L, Machala M, et al. Antibody response to influenza vaccine in children with severe and mild hemophilia. Int J Pediatr Hematol Oncol. In press
111.
McMichael AF, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309: 13–7PubMedCrossRef
Metadata
Title
Humoral Immune Response to Influenza Vaccination in Patients from High Risk Groups
Authors
Professor Lidia B. Brydak
Magdalena Machala
Publication date
01-07-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue 1/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200060010-00004

Other articles of this Issue 1/2000

Drugs 1/2000 Go to the issue

Adis Drug Evaluation

Ropinirole

Review Article

Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis

Disease Management

A Rational Approach to Drug Therapy of Type 2 Diabetes Mellitus

Adis Drug Evaluation

Dalteparin

Leading Article

Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?

Review Article

Newer Anticonvulsants